DDInter1187 DDInter1763
A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Methylergometrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Methylergometrine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Methylergometrine {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Methylergometrine {u} (Compound) downregulates {v} (Gene) DNAJB1
DNAJB1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Methylergometrine {u} (Compound) causes {v} (Side Effect) Convulsion
Convulsion {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Methylergometrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Methylergometrine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Methylergometrine {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Methylergometrine {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is associated with {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Methylergometrine {u} (Compound) downregulates {v} (Gene) DNAJB1
DNAJB1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Methylergometrine (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Temsirolimus (Compound)
Methylergometrine (Compound) downregulates DNAJB1 (Gene) and DNAJB1 (Gene) is downregulated by Temsirolimus (Compound)
Methylergometrine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Temsirolimus (Compound)
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Methylergometrine (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Methylergometrine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is associated with kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)
Methylergometrine (Compound) downregulates DNAJB1 (Gene) and DNAJB1 (Gene) is upregulated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)